Oxycodon Hcl Retard Teva

Active Ingredient:: Oxycodone Hydrochloride
Origin:: EU

Oxycodon Hcl Retard Teva (Oxycodone Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxycodon Hcl Retard Teva, is an opioid analgesic presented as a prolonged‑release oral tablet for oral use. It is indicated for the management of moderate to severe pain in adult patients when continuous, around‑the‑clock analgesia is required. GNH India supplies Oxycodon Hcl Retard Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Oxycodon Hcl Retard Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Teva Nederland B.V.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxycodone Hydrochloride is an opioid analgesic that acts on the central nervous system to relieve pain.

Chronic cancer‑related pain: provides sustained relief for patients with persistent tumor‑associated pain.
Post‑operative pain: maintains analgesia after major surgical procedures requiring continuous pain control.
Severe musculoskeletal pain: alleviates intense pain from conditions such as advanced osteoarthritis or spinal disorders.
Chronic non‑cancer pain: offers long‑acting relief for patients with severe, refractory pain not adequately managed by non‑opioid agents.

How It Works

Oxycodone Hydrochloride binds primarily to μ‑opioid receptors in the central nervous system, activating inhibitory G‑protein pathways that reduce neuronal excitability and diminish the perception of pain. This receptor activation also modulates neurotransmitter release, contributing to its analgesic effect while producing typical opioid‑related central effects.

Side Effects

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects

Constipation: reduced gastrointestinal motility leading to hard stools.
Nausea: sensation of queasiness often accompanied by an urge to vomit.
Drowsiness: increased sleepiness or reduced alertness.
Dry mouth: decreased salivary flow causing oral discomfort.
Lightheadedness: transient feeling of faintness, especially on standing.
Sweating: excessive perspiration unrelated to temperature or activity.

Serious or Rare Side Effects

Respiratory depression: slowed or shallow breathing that can be life‑threatening.
Severe hypotension: marked drop in blood pressure causing dizziness or fainting.
Opioid dependence or addiction: compulsive use despite harmful consequences.
Seizures: rare occurrence of convulsive episodes.
Anaphylaxis: acute allergic reaction with airway compromise.
Adrenal insufficiency: impaired cortisol production leading to fatigue and weakness.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient history and monitor for potential complications.

Assess renal and hepatic function: adjust use if organ impairment is present.
Evaluate for respiratory disorders: avoid in patients with severe asthma or COPD.
Screen for substance‑use disorder: consider risk of dependence.
Use caution in the elderly: increased sensitivity to sedative effects.
Avoid concomitant CNS depressants: may potentiate sedation and respiratory depression.
Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Oxycodone Hydrochloride can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

Benzodiazepines: combined use can cause profound respiratory depression and excessive sedation.
Barbiturates: may intensify central nervous system depression and increase overdose risk.
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise oxycodone plasma levels, heightening toxicity.

Moderate Interactions (Monitor Closely)

CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): modestly increase oxycodone concentrations.
Anticholinergic agents: may worsen constipation and urinary retention.
Antihistamines: can add to drowsiness and dizziness.

Frequently Asked Questions

Oxycodon Hcl Retard Teva contains oxycodone hydrochloride, an opioid analgesic prescribed for the management of moderate to severe pain that requires continuous, around‑the‑clock relief, such as chronic cancer pain, post‑operative pain and severe musculoskeletal pain.

Oxycodone hydrochloride binds to μ‑opioid receptors in the brain and spinal cord, activating inhibitory pathways that lower neuronal excitability and reduce the transmission of pain signals, resulting in analgesia.

The dose is individualized by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and other clinical factors. No fixed regimen is provided here.

Opioid analgesics, including oxycodone, are generally classified as high‑risk in pregnancy and are excreted in breast milk. Use is only considered when the potential benefit justifies the potential risk to the fetus or infant, and it should be decided by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with immediate‑release opioids, this formulation provides prolonged plasma concentrations, allowing twice‑daily dosing and more stable pain control. It differs from morphine‑based products in its potency and receptor binding profile, offering an alternative when clinicians seek a strong μ‑opioid agonist with a longer duration of action.

Store the tablets below 25°C in their original container, protected from moisture, heat and direct sunlight. Keep out of reach of children and unauthorized personnel.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.